5665
Overview
Efficient generation of large quantities of functional T cells is a major bottleneck in the development of T cell-based immunotherapies. Conventional ex-vivo culturing methods often lead to cell death or functional loss. This technology introduces a synthetic immune niche by coating culture surfaces with immobilized ICAM1 and CCL21, combined with soluble IL-6, to mimic the natural lymphoid microenvironment. These conditions promote robust T cell proliferation while enhancing cytotoxic function, including granzyme B expression and tumor-killing capacity.
Applications
- Expansion of CD4+ and CD8+ T cells for cancer immunotherapy
- Production of antigen-specific T cells (e.g., neoantigen-specific T cells)
- Enhancement of CAR-T and TIL expansion and activity
- Adoptive cell therapy using functionalized T cells
- Ex-vivo stimulation of tumor-infiltrating T cells from patient biopsies
Differentiation
- Significantly improves proliferation and viability of T cells ex-vivo
- Enhances cytotoxic function (e.g., granzyme B levels, tumor suppression)
- Compatible with CAR-T and neoantigen-targeted therapies
- Simple coating-based method, scalable and easy to implement
Development Stage
Validated in murine CD4+ and CD8+ T cells in vitro and in vivo (tumor models).
Demonstrated efficacy in expanding functional human CAR-Ts and TILs.
Patent Status:
USA Granted: 11,932,871
Contact for more information
